Trials / Completed
CompletedNCT01895439
Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis
Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- University of Jordan · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
1. Expanding and priming Bone Marrow (BM)- Mesenchymal Stem Cells (MSCs) to a clinical scale according to Good Laboratory Practice using xenogenic free media instead of the previously used FCS. 2. Assessing the safety of injecting autologous BM-MSCs to Multiple Sclerosis (MS)patients who fail to respond to conventional treatment. 3. Assessing the therapeutic benefits on the participants in the trial as per established methods.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous Mesenchymal Stem Cells |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2013-07-10
- Last updated
- 2017-05-02
Locations
1 site across 1 country: Jordan
Source: ClinicalTrials.gov record NCT01895439. Inclusion in this directory is not an endorsement.